Actively Recruiting
Phase 3 Study of Treprostinil Palmitil Inhalation Powder Versus Placebo in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease
Led by Insmed Incorporated · Updated on 2026-10-26
344
Participants Needed
186
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults with pulmonary hypertension associated with interstitial lung disease PH-ILD to evaluate the effects of a 24-week daily treatment using Treprostinil Palmitil Inhalation Powder TPIP compared to a placebo. This phase 3, randomized, double-blind, placebo-controlled study aims to assess how TPIP impacts exercise capacity in this group. Participants will receive either TPIP once daily, starting at 80 micrograms and increasing to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled via a capsule-based dry powder inhaler. The treatment period lasts for 24 weeks, and both groups use the same type of inhalation device to maintain blinding. During the study, participants will undergo assessments including the 6-minute walk test to measure exercise capacity and blood tests to track heart-related biomarkers like NT-proBNP. Researchers will monitor clinical worsening events, adverse effects, and plasma drug levels throughout the 24-week treatment. The study is designed to provide detailed information about TPIPs impact on PH-ILD over this period.
CONDITIONS
Brief Title
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Research Team
I
Insmed Medical Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here